Pangen Biotech Inc.
222110
Company Summary
Quarterly Performance
Revenue
Operating Margin
Market Sentiment
※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate
Financials
Excel
No financial data is available for this period.
~
Quarterly
Annual
*Values beyond the fourth decimal place of the unit are displayed as '0/-0'
Financial Indicator Forecast
※ These forecasts are simple AI estimates
based on historical data and may differ from actual results.
Company Overview
as of June 2026
Pangen Biotech Inc. built GMP facilities for biopharmaceutical production from its early days, and using these GMP facilities together with its proprietary PanGen CHO-TECH(TM) technology and biopharmaceutical commercialization technology, the company carries out the following businesses: the production and sale of the biosimilar EPO drug; contract manufacturing (CMO) and development technology transfer services (CDO) for biopharmaceuticals, including non-clinical and clinical samples; and biopharmaceutical development. Biosimilar drug production and sale business: EPO drug, an anemia treatment for chronic renal failure patients. Biopharmaceutical CMO and development technology transfer (CDO) business: CDMO (Contract Development and Manufacturing Organization). Biopharmaceutical development business: Factor VIII, a treatment for hemophilia A; Aflibercept, a treatment for macular degeneration and macular edema; an anti-SFTSV antibody treatment for severe fever with thrombocytopenia syndrome; and G-CSF, an adjuvant for cancer treatment. The biosimilar EPO drug, an anemia treatment for chronic renal failure patients that the company successfully developed on its own, received marketing authorization under the product name Erysaa from the Malaysian health authority in January 2019 and has been sold in the Malaysian market since March 2019; it received marketing authorization under the product name Panpotin in Korea in November 2019 and domestic sales began in February 2020; in the Philippines it received marketing authorization for 4000 IU (product name Erysaa) in August 2022 and for 2000 IU (product name Erysaa) in October 2022, and has been sold there since December 2022; and in Saudi Arabia it obtained marketing authorization (product name: Panpotin) in May 2023 and has been sold there since March 2024.
Representative Director
Yoon Jaeseung
Founded
January 29, 2010
Corporation Type
KOSDAQ
Industry Classification
Manufacture of medicaments
Corporate number
13111-0248194
Business number
129-86-42227
Phone Number
031-733-9165
Fax Number
031-733-9167
Website
www.pangen.com
Company Address
306 Sinwon-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do
Products & Services
Comments